electroCore Rejoins Ranks of Exploding Speculative COVID-19 Stocks

Photo of Jon C. Ogg
By Jon C. Ogg Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
electroCore Rejoins Ranks of Exploding Speculative COVID-19 Stocks

© Michael Ciaglo / Getty Images News via Getty Images

Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing, vaccines, treatments or evebn cleaning products that can help win in the battle against COVID-19. One such company which was seeing massive after-hours buying activity on Thursday was electroCore, Inc. (NASDAQ: ECOR).

Traders and investors should be warned that electroCore had a mere $58 million market capitalization as of Thursday’s closing bell. The stock more than doubled on over 10 million shares trading hands in the after-hours. elctroCore has also seen prior pops with similar trading around its other COVID-19 news announcements.

electroCore calls itself a commercial-stage bioelectronic medicine company, but the company’s entire 2019 revenue was just 2.3 million. Thursday’s announcement was additional information about the availability, distribution and pricing for the gammaCore Sapphire™ CV non-invasive vagus nerve stimulation (nVNS) therapy. This is also under the company’s Emergency Use Authorization to use at home or in a healthcare setting.

The company’s target is to acutely treat adult patients with known or suspected COVID-19 cases who are experiencing asthma-related dyspnea and reduced airflow, as well as for whom approved drug therapies are not well tolerated or which are not provide sufficient symptom relief.

[nativounit]

According to the company’s statement, the gammaCore Sapphire CV is being made available and the company’s stated goal is to make this process as simple as possible for all of the patients, physicians and hospitals that would like to it. The company has also engaged a specialty pharmacy outfit called Premier Pharmacy Services to support distribution efforts.

24/7 Wall St. has covered electroCore in prior coronavirus coverage, but we would also point out that this stock has trended drastically lower since its 2018 IPO coverage.

On last look, Thursday’s after-hours trading session had a 151% gain to $3.87. This stock also closed at just $1.54 on Thursday’s closing bell, and it has a 52-week range of $0.32 to $5.64.

This looks like yet another speculative micro-cap stocks where speculators and daytraders are entirely on their own.

[wallst_email_signup]

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618